Treatment of atherosclerotic intracranial arterial stenosis

Stroke

Volumn 40, Issue 6, 2009, Pages 2257-2261

  Turan, Tanya N ^a   Derdeyn, Colin P ^b   Fiorella, David ^c   Chimowitz, Marc I ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Antithrombotic therapy; Intracranial stenosis; Intracranial stenting

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; WARFARIN; FIBRINOLYTIC AGENT;

BRAIN ATHEROSCLEROSIS; CLINICAL TRIAL; HUMAN; HYPERLIPIDEMIA; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RECURRENT DISEASE; RESTENOSIS; REVIEW; RISK FACTOR; RISK MANAGEMENT; SECONDARY PREVENTION; STENT; STROKE; ANGIOPLASTY; ATHEROSCLEROSIS; CEREBRAL ARTERY DISEASE; FIBRINOLYTIC THERAPY; STENOSIS, OCCLUSION AND OBSTRUCTION;

ANGIOPLASTY; ATHEROSCLEROSIS; CEREBRAL ARTERIAL DISEASES; CONSTRICTION, PATHOLOGIC; FIBRINOLYTIC AGENTS; HUMANS; RISK FACTORS; STENTS; STROKE; THROMBOLYTIC THERAPY;

EID: 66849093888     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.537589     Document Type: Review

References (41)

1. Gorelick PB, Wong KS, Bae HJ, Pandey DK. Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier. Stroke 2008;39:2396-2399.
2. Wong LK. Global burden of intracranial atherosclerosis. Int J Stroke 2006;1:158-159.
3. Sacco RL, Kargman D, Gu Q, Zamanillo MC. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction: The Northern Manhattan Stroke Study. Stroke 1995;26:14-20.
4. Chimowitz MI, Kokkinos J, Strong J, Brown M, Levine SR, Silliman S, Pessin MS, Weichel E, Sila CA, Furlan AJ, Kargman DE, Sacco RL, Wityk RJ, Ford G, Fayad PB; for the Warfarin-Aspirin Symptomatic Intracranial Disease Study Group. The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology. 1995;45:1488-1493.
5. Caplan LR. Caplan's Stroke: A Clinical Approach. Third Edition. Boston: Butterworth-Heinemann; 2000.
6. Turan TN, Lynn M, Chimowitz MI. Survey of US stroke neurologists and neurointerventionalists on treatment choices for intracranial stenosis. Abstract. Cerebrovasc Dis. 2007;23(suppl 2):131.
7. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, KasnerSE, BeneschCG, SilaCA, Jovin TG, Romano JG; for the Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352: 1305-1316.
8. Thijs VN, Albers GW. Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy. Neurology. 2000;55: 490-497.
9. Kasner SE, Lynn MJ, Chimowitz MI, Frankel MR, Howlett-Smith H, Hertzberg VS, Chaturvedi S, Levine SR, Stern BJ, Benesch CG, Jovin TG, Sila CA, Romano JG. Warfarin Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Warfarin vs aspirin for symptomatic intracranial stenosis: subgroup analyses from WASID. Neurology. 2006;67:1275-1278.
10. Turan TN, Maidan L, Cotsonis G, Lynn MJ, Romano JG, Levine SR, Chimowitz MI. Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis. Stroke 2009;40:505-509.
11. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; the PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238-1251.
12. Kwon S, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, Lee JH, Kim JS. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005;36: 782-786.
13. Wong KS, Chen C, Ng PW, Tsoi TH, Li HL, Fong WC, Yeung J, Wong CK, Yip KK, Gae H, Wong HB; for the FISS-tris Study Investigators. Low-molecular-weight heparin compared with aspirin forthe treatment of acute ischemic stroke in Asian patients with large artery occlusive disease: a randomized study. Lancet Neurology. 2007;6:407-413.
14. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
15. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
16. Chaturvedi S, Turan TN, Lynn MJ, Kasner SE, Romano J, Cotsonis G, Frankel MR, Chimowitz MI; for the WASID Study Group. Risk factor status and vascular events in patients with symptomatic intracranial stenosis. Neurology. 2007;69:2063-2068.
17. Turan TN, Cotsonis G, Lynn MJ, Chaturvedi S, Chimowitz M; Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Relationship between blood pressure and stroke recurrence in patients with intracranial arterial stenosis Circulation. 2007;115:2969-2975.
18. Goldstein LB, Amarenco P, Szarek M, Callahan A III, Hennerici M, Sillesen H, Zivin JA, Welch KM; for the SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008;70:2364-2370.
19. Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke 2008;39:497-502.
20. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGETrial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516.
21. Sundt TM Jr, Smith HC, Campbell JK, Vlietstra RE, Cucchiara RF, Stanson AW. Transluminal angioplasty for basilar artery stenosis. Mayo Clin Proc. 1980;55:673-680.
22. Derdeyn CP, Chimowitz MI. Angioplasty and stenting for atherosclerotic intracranial stenosis: rationale for a randomized clinical trial. Neuroimaging Clin N Am. 2007;17:355-363.
23. Connors JJ III, Wojak JC. Percutaneous transluminal angioplasty for intracranial atherosclerotic lesions: evolution of technique and short-term results. J Neurosurg. 1999;9:415-423.
24. Marks MP, Wojak JC, Al-Ali F, Jayaraman M, Marcellus ML, Connors JJ, Do HM. Angioplasty for symptomatic intracranial stenosis: clinical outcome. Stroke 2006;37:1016-1020.
25. Qureshi AI, Hussein HM, El-Gengaihy A, Abdelmoula M, Suri MF. Concurrent comparison of outcomes of primary angioplasty and of stent placement in high-risk patients with symptomatic intracranial stenosis. Neurosurgery. 2008;62:1053-1062.
26. Mazighi M, Yadav JS, Abou-Chebl A. Durability of endovascular therapy for symptomatic intracranial atherosclerosis. Stroke 2008;39:1766-1769.
27. Leung TW, Kwon Su, Wong KS. Management of patients with symptomatic intracranial atherosclerosis. Int J Stroke 2006;1:20-25.
28. SSYLVIA Study Investigators. Stenting of symptomatic atherosclerotic lesions in the vertebral or intracranial arteries (SSYLVIA): study results. Stroke 2004;35:1388-1392.
29. Bose A, Hartmann M, Henkes H, Liu HM, Teng MM, Szikora I, Berlis A, Reul J, Yu SC, Forsting M, Lui M, Lim W, Sit SP. A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses: the Wingspan study. Stroke 2007;38:1531-1537.
30. Fiorella D, Levy EI, Turk AS, Albuquerque FC, Niemann DB, Aagaard-Kienitz B, Hanel RA, Woo H, Rasmussen PA, Hopkins LN, Masaryk TJ, McDougall CG. US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results. Stroke 2007;38:881-887.
31. Kasner S, Chimowitz M, Lynn M, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Benesch CG, Sila CA, Jovin TG, Romano JG, Cloft HJ; for the Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Predictors of ischemic stroke in the territory of asymptomatic intracranial arterial stenosis. Circulation. 2006; 113:555-563.
32. Jiang WJ, Xu XT, Du B, Dong KH, Jin M, Wang QH, Ma N. Comparison of elective stenting of severe vs moderate intracranial atherosclerotic stenosis. Neurology. 2007;68:420-426.
33. Zaidat OO, Klucznik R, Alexander MJ, Chaloupka J, Lutsep H, Barnwell S, Mawad M, Lane B, Lynn MJ, Chimowitz M; NIH Multi-center Wingspan Intracranial Stent Registry Study Group. The NIH registry on use of the Wingspan stent for symptomatic 70-99% intracranial arterial stenosis. Neurology. 2008;70:1518-1524.
34. Albuquerque FC, Levy EI, Turk AS, Niemann DB, Aagaard-Kienitz B, Pride GL Jr, Purdy PD, Welch BG, Woo HH, Rasmussen PA, Hopkins LN, Masaryk TJ, McDougall CG, Fiorella DJ. Angiographic patterns of Wingspan in-stent restenosis. Neurosurgery. 2008;63:23-27.
35. Turk AS, Levy EI, Albuquerque FC, Pride GL Jr, Woo H, Welch BG, Niemann DB, Purdy PD, Aagaard-Kienitz B, Rasmussen PA, Hopkins LN, Masaryk TJ, McDougall CG, Fiorella D. Influence of patient age and stenosis location on wingspan in-stent restenosis. Am J Neuroradiol. 2008;29:23-27.
36. Levy EI, Turk AS, Albuquerque FC, Niemann DB, Aagaard-Kienitz B, Pride L, Purdy P, Welch B, Woo H, Rasmussen PA, Hopkins LN, Masaryk TJ, McDougall CG, Fiorella DJ. Wingspan in-stent restenosis and thrombosis: incidence, clinical presentation, and management. Neurosurgery. 2007;61:644-650.
37. Fiorella D, Woo HH. Emerging endovascular therapies for symptomatic intracranial atherosclerotic disease. Stroke 2007;38:2391-2396.
38. Jiang WJ, Xu XT, Jin M, Du B, Dong KH, Dai JP. Apollo stent for symptomatic atherosclerotic intracranial stenosis: study results. Am J Neuroradiol. 2007;28:830-834.
39. Kurre W, Berkefeld J, Sitzer M, Neumann-Haefelin T, du Mesnil de Rochemont R. Treatment of symptomatic high-grade intracranial stenoses with the balloon-expandable Pharos stent: initial experience. Neuroradiology. 2008;50:701-708.
40. Siddiq F, Vazquez G, Memon MZ, Suri MF, Taylor RA, Wojak JC, Chaloupka JC, Qureshi AI. Comparison of primary angioplasty with stent placement for treating symptomatic intracranial atherosclerotic diseases: a multicenter study. Stroke 2008;39:2505-2510.
41. Feldmann E, Wilterdink JL, Kosinski A, Lynn M, Chimowitz MI, Sarafin J, Smith HH, Nichols F, Rogg J, Cloft HJ, Wechsler L, Saver J, Levine SR, Tegeler C, Adams R, Sloan M; The Stroke Outcomes and Neuro-imaging of Intracranial Atherosclerosis (SONIA) Trial Investigators. The Stroke Outcomes and Neuroimaging of Intracranial Atherosclerosis (SONIA) trial. Neurology. 2007;68:2099-2106.